O
Osivax
Biotech & Life Sciences · Lyon, France · Founded 2017
A company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections MoreLess
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: www.osivax.com
Company overview
Osivax company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lyon, France
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 75.8
Valuation & funding
Osivax funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2025 | $20M | — | US Biomedical Advanced Research and Development Authority | ↗ |
| SERIES BOther financing | Mar 2025 | $11M | $44M | Meiji Seika Pharma | ↗ |
| GRANTOther financing | Dec 2023 | $1.5M | — | US National Institute of Allergy and Infectious Diseases | ↗ |
| GRANTOther financing | Mar 2023 | $1M | — | Bill & Melinda Gates Foundation | ↗ |
| GRANTOther financing | Jun 2022 | $11M | — | Bpifrance | ↗ |
| CONVERTIBLEOther financing | Jul 2021 | EIC Fund | — | ||
| CONVERTIBLEOther financing | Jul 2021 | EIC Fund | — | ||
| GRANTOther financing | Jul 2020 | Bpifrance | — | ||
| EARLY VCOther financing | Mar 2020 | EIC Fund | — | ||
| GRANTOther financing | Mar 2020 | European Innovation Council | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $85K | 0% | −$2.1M | -2419.4% |
| 2025 | $85K | 0% | −$2.1M | -2419.4% |
| 2024 | $85K | 0% | −$2.1M | -2419.4% |
| 2023 | $85K | 0% | −$2.1M | -2419.4% |
| 2022 | $85K | 0% | −$2.1M | -2419.4% |
| 2021 | $85K | 0% | −$2.1M | -2419.4% |
| 2020 | $85K | — | −$2.1M | -2419.4% |
Growth signals
Osivax website traffic
Latest recorded traffic for Osivax is 390 monthly website visits, down 81.4% over the last three months. Osivax's team grew 5.3% over the past year.
Comparisons
Osivax compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Osivax's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Osivax has talent and traffic
team presence
In the news
Latest news about Osivax
Recent press, funding announcements, and product moves mentioning Osivax — open to read from the original sources.
Market sentiment
What the market is saying about Osivax
An AI-synthesized read of the highest-engagement posts about Osivax on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osivax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.